These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7181463)

  • 1. [Effect of crystallinity on the rate of solution of oxytetracycline hydrochloride].
    Grakovskaia LK; Nesterova LIa
    Antibiotiki; 1982 Nov; 27(11):815-20. PubMed ID: 7181463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal modification of dipyridamole using different solvents and crystallization conditions.
    Adhiyaman R; Basu SK
    Int J Pharm; 2006 Sep; 321(1-2):27-34. PubMed ID: 16842943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface characteristics and dissolution behavior of plasma-sprayed hydroxyapatite coating.
    Sun L; Berndt CC; Khor KA; Cheang HN; Gross KA
    J Biomed Mater Res; 2002 Nov; 62(2):228-36. PubMed ID: 12209943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of auxiliary substances on the bioavailability of tetracycline hydrochloride capsules (an in vitro study)].
    Grakovskaia LK; Nesterova LIa; Okhotnikova VF; Zak AF; Ermolova OB
    Antibiotiki; 1978 Mar; 23(3):215-9. PubMed ID: 637528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale cellulose films with different crystallinities and mesostructures--their surface properties and interaction with water.
    Aulin C; Ahola S; Josefsson P; Nishino T; Hirose Y; Osterberg M; Wågberg L
    Langmuir; 2009 Jul; 25(13):7675-85. PubMed ID: 19348478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the effect of the oxytetracycline crystallization conditions on the process indices].
    Lin'kov GI; Zhukovskaia SA
    Antibiotiki; 1975 Jun; 20(7):591-5. PubMed ID: 5049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring solid forms of oxytetracycline hydrochloride.
    Bueno MS; Miñambres GG; Bongioanni A; Chattah AK; Aiassa V; Longhi MR; Garnero C
    Int J Pharm; 2020 Jul; 585():119496. PubMed ID: 32504775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioavailability of levomycetin preparations for oral use].
    Batuashvili TA; Zak AF
    Antibiotiki; 1983 Oct; 28(10):751-4. PubMed ID: 6651263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach.
    Mutalik S; Anju P; Manoj K; Usha AN
    Int J Pharm; 2008 Feb; 350(1-2):279-90. PubMed ID: 17945447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide.
    Hassan MA; Sheikh Salem M; Sallam E; al-Hindawi MK
    Acta Pharm Hung; 1997; 67(2-3):81-8. PubMed ID: 9223758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of physicomechanical properties of carbamazepine by recrystallization at different pH values.
    Javadzadeh Y; Mohammadi A; Khoei NS; Nokhodchi A
    Acta Pharm; 2009 Jun; 59(2):187-97. PubMed ID: 19564143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of crystal morphology and mill type on milling induced crystal disorder.
    Chikhalia V; Forbes RT; Storey RA; Ticehurst M
    Eur J Pharm Sci; 2006 Jan; 27(1):19-26. PubMed ID: 16246535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutical studies on sulphadimidine modifications.
    Hadi IA; Mezösi J; Kedvessy G; Morvay J
    Pharmazie; 1977 Dec; 32(12):791-3. PubMed ID: 613320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystallization kinetics of amorphous lactose, whey-permeate and whey powders.
    Ibach A; Kind M
    Carbohydr Res; 2007 Jul; 342(10):1357-65. PubMed ID: 17445785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryogenic liquids, nanoparticles, and microencapsulation.
    Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of oxytetracycline hydrochloride in eye-drops, prepared in pharmacies.
    Izer K; Török I; Pintér-Magyar G
    Acta Pharm Hung; 1994 Mar; 64(2):63-6. PubMed ID: 8017210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation into the subambient behavior of aqueous mannitol solutions using temperature-controlled Raman microscopy.
    Beattie JR; Barrett LJ; Malone JF; McGarvey JJ; Nieuwenhuyzen M; Kett VL
    Eur J Pharm Biopharm; 2007 Sep; 67(2):569-78. PubMed ID: 17481870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of magnesium-substituted hydroxyapatite powders by the mechanochemical-hydrothermal method.
    Suchanek WL; Byrappa K; Shuk P; Riman RE; Janas VF; TenHuisen KS
    Biomaterials; 2004 Aug; 25(19):4647-57. PubMed ID: 15120511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solvent change co-precipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug.
    Sertsou G; Butler J; Hempenstall J; Rades T
    J Pharm Pharmacol; 2002 Aug; 54(8):1041-7. PubMed ID: 12195817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.